Pre-made Gontivimab biosimilar ( Bispecific Single Domains (VH-VH'-VH'), anti-RSV gpF therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-251
Anti-RSV gpF therapeutic antibody (Pre-made Gontivimab biosimilar,Bispecific Single Domains (VH-VH'-VH')) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Gontivimab is a monoclonal antibody-derived therapeutic protein (Nanobodies®) (designated as ALX 0171), being developed by Ablynx (a subsidiary of Sanofi) as a once-daily treatment of patients with respiratory syncytial virus (RSV) infections.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-RSV gpF therapeutic antibody (Pre-made Gontivimab biosimilar,Bispecific Single Domains (VH-VH'-VH'))|
|Format||Bispecific Single Domains (VH-VH'-VH')|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Discontinued||Respiratory syncytial virus infections|